Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Borkowski

Interventional Cardiology New Britain, CT Medical Doctor

NPI 1801852074 CMS profile 36250

One Liberty Square, New Britain, CT 06051

Open in the dashboard

General payments

$7,822

456 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robert Borkowski of New Britain, CT is reported in the CMS Open Payments database as having received $7,822 across 456 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $25 1
2022 General $510 27
2021 General $2,673 146
2020 General $1,858 116
2019 General $2,756 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Borkowski
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Robert Borkowski were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Robert Borkowski Interventional Cardiology median Middle half National median
2019 $2,756 $1,097 $329–$3,048 $163
2020 $1,858 $473 $161–$1,480 $114
2021 $2,673 $677 $233–$1,827 $132
2022 $510 $978 $333–$2,724 $149
2023 $25 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $1,396 95 payments
  2. Amarin Pharma Inc. $1,014 73 payments
  3. Pfizer Inc. $743 33 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $643 31 payments
  5. Amgen Inc. $468 23 payments
  6. Novartis Pharmaceuticals Corporation $396 31 payments
  7. Esperion Therapeutics, Inc. $387 18 payments
  8. AstraZeneca Pharmaceuticals LP $366 26 payments
  9. Alnylam Pharmaceuticals Inc. $362 14 payments
  10. E.R. Squibb & Sons, L.L.C. $339 21 payments
  11. Other $1,708 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,751 449 payments
  2. Education $71 7 payments
Products named General payments · program years 2019–2023
  1. XARELTO $1,396 95 payments
  2. Vascepa $719 54 payments
  3. JARDIANCE $471 21 payments
  4. Repatha $468 23 payments
  5. VYNDAQEL $417 24 payments
  6. ELIQUIS Cardiovascular;Metabolic Disease $408 24 payments
  7. NEXLETOL $387 18 payments
  8. ENTRESTO $370 29 payments
  9. ONPATTRO $362 14 payments
  10. ELIQUIS Cardiovascular $318 20 payments
  11. Other $2,982 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

456 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record